305 related articles for article (PubMed ID: 34914185)
1. Fibroblast Activation Protein-α Responsive Peptide Assembling Prodrug Nanoparticles for Remodeling the Immunosuppressive Microenvironment and Boosting Cancer Immunotherapy.
Sun M; Yao S; Fan L; Fang Z; Miao W; Hu Z; Wang Z
Small; 2022 Mar; 18(9):e2106296. PubMed ID: 34914185
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
3. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
[TBL] [Abstract][Full Text] [Related]
4. Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy.
Choi J; Shim MK; Yang S; Hwang HS; Cho H; Kim J; Yun WS; Moon Y; Kim J; Yoon HY; Kim K
ACS Nano; 2021 Jul; 15(7):12086-12098. PubMed ID: 34165970
[TBL] [Abstract][Full Text] [Related]
5. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
6. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment.
Zhu X; Li C; Lu Y; Liu Y; Wan D; Zhu D; Pan J; Ma G
Acta Biomater; 2021 Jan; 119():337-348. PubMed ID: 33166712
[TBL] [Abstract][Full Text] [Related]
8. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
9. A Three-In-One Assembled Nanoparticle Containing Peptide-Radio-Sensitizer Conjugate and TLR7/8 Agonist Can Initiate the Cancer-Immunity Cycle to Trigger Antitumor Immune Response.
Zhu X; Wang X; Li B; Zhang Y; Chen Y; Zhang W; Wang Y; Zhai W; Liu Z; Liu S; Sun J; Chen Z; Gao Y
Small; 2022 May; 18(20):e2107001. PubMed ID: 35434938
[TBL] [Abstract][Full Text] [Related]
10. Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy.
Zhu L; Li J; Guo Z; Kwok HF; Zhao Q
J Nanobiotechnology; 2022 Dec; 20(1):521. PubMed ID: 36496381
[TBL] [Abstract][Full Text] [Related]
11. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
Zang X; Song J; Yi X; Piyu J
J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
[TBL] [Abstract][Full Text] [Related]
12. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
[TBL] [Abstract][Full Text] [Related]
13. Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment.
Feng B; Zhou F; Hou B; Wang D; Wang T; Fu Y; Ma Y; Yu H; Li Y
Adv Mater; 2018 Sep; 30(38):e1803001. PubMed ID: 30063262
[TBL] [Abstract][Full Text] [Related]
14. A Nanobody-Bioorthogonal Catalyst Conjugate Triggers Spatially Confined Prodrug Activation for Combinational Chemo-immunotherapy.
Zhao Z; Wang X; Wang J; Li Y; Lin W; Lu K; Chen J; Xia W; Mao ZW
J Med Chem; 2023 Sep; 66(17):11951-11964. PubMed ID: 37590921
[TBL] [Abstract][Full Text] [Related]
15. Transformable prodrug nanoplatform
Yang W; Yi J; Zhu R; Guo Y; Zhang K; Cao Y; Li X; Zhang J; Zhang Z; Li Y; Chen X
Theranostics; 2023; 13(6):1906-1920. PubMed ID: 37064869
[No Abstract] [Full Text] [Related]
16. PD-1 Blockade for Improving the Antitumor Efficiency of Polymer-Doxorubicin Nanoprodrug.
Gao F; Zhang C; Qiu WX; Dong X; Zheng DW; Wu W; Zhang XZ
Small; 2018 Sep; 14(37):e1802403. PubMed ID: 30129176
[TBL] [Abstract][Full Text] [Related]
17. Self-Assembled Nanoparticles from the Amphiphilic Prodrug of Resiquimod for Improved Cancer Immunotherapy.
Li JX; Shu N; Zhang YJ; Tong QS; Wang L; Zhang JY; Du JZ
ACS Appl Mater Interfaces; 2024 May; 16(20):25665-25675. PubMed ID: 38735053
[TBL] [Abstract][Full Text] [Related]
18. Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded
Wei B; Pan J; Yuan R; Shao B; Wang Y; Guo X; Zhou S
Nano Lett; 2021 May; 21(10):4231-4240. PubMed ID: 33998789
[TBL] [Abstract][Full Text] [Related]
19. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.
Song S; Shim MK; Yang S; Lee J; Yun WS; Cho H; Moon Y; Min JY; Han EH; Yoon HY; Kim K
Bioact Mater; 2023 Oct; 28():358-375. PubMed ID: 37334068
[TBL] [Abstract][Full Text] [Related]
20. Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade.
Zhou F; Feng B; Yu H; Wang D; Wang T; Ma Y; Wang S; Li Y
Adv Mater; 2019 Apr; 31(14):e1805888. PubMed ID: 30762908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
